638 related articles for article (PubMed ID: 25647019)
1. BRD4 promotes pancreatic ductal adenocarcinoma cell proliferation and enhances gemcitabine resistance.
Wang YH; Sui YN; Yan K; Wang LS; Wang F; Zhou JH
Oncol Rep; 2015 Apr; 33(4):1699-706. PubMed ID: 25647019
[TBL] [Abstract][Full Text] [Related]
2. OSI-027 inhibits pancreatic ductal adenocarcinoma cell proliferation and enhances the therapeutic effect of gemcitabine both in vitro and in vivo.
Zhi X; Chen W; Xue F; Liang C; Chen BW; Zhou Y; Wen L; Hu L; Shen J; Bai X; Liang T
Oncotarget; 2015 Sep; 6(28):26230-41. PubMed ID: 26213847
[TBL] [Abstract][Full Text] [Related]
3. TM4SF1 Promotes Gemcitabine Resistance of Pancreatic Cancer In Vitro and In Vivo.
Cao J; Yang J; Ramachandran V; Arumugam T; Deng D; Li Z; Xu L; Logsdon CD
PLoS One; 2015; 10(12):e0144969. PubMed ID: 26709920
[TBL] [Abstract][Full Text] [Related]
4. Simvastatin attenuates macrophage-mediated gemcitabine resistance of pancreatic ductal adenocarcinoma by regulating the TGF-β1/Gfi-1 axis.
Xian G; Zhao J; Qin C; Zhang Z; Lin Y; Su Z
Cancer Lett; 2017 Jan; 385():65-74. PubMed ID: 27840243
[TBL] [Abstract][Full Text] [Related]
5. Melatonin overcomes gemcitabine resistance in pancreatic ductal adenocarcinoma by abrogating nuclear factor-κB activation.
Ju HQ; Li H; Tian T; Lu YX; Bai L; Chen LZ; Sheng H; Mo HY; Zeng JB; Deng W; Chiao PJ; Xu RH
J Pineal Res; 2016 Jan; 60(1):27-38. PubMed ID: 26445000
[TBL] [Abstract][Full Text] [Related]
6. MAP3K10 promotes the proliferation and decreases the sensitivity of pancreatic cancer cells to gemcitabine by upregulating Gli-1 and Gli-2.
An Y; Cai B; Chen J; Lv N; Yao J; Xue X; Tu M; Tang D; Wei J; Jiang K; Wu J; Li Q; Gao W; Miao Y
Cancer Lett; 2013 Feb; 329(2):228-35. PubMed ID: 23178452
[TBL] [Abstract][Full Text] [Related]
7. TRIM29 facilitates gemcitabine resistance via MEK/ERK pathway and is modulated by circRPS29/miR-770-5p axis in PDAC.
Huang W; Hu X; He X; Pan D; Huang Z; Gu Z; Huang G; Wang P; Cui C; Fan Y
Drug Resist Updat; 2024 May; 74():101079. PubMed ID: 38518727
[TBL] [Abstract][Full Text] [Related]
8. TRIM11 suppresses ferritinophagy and gemcitabine sensitivity through UBE2N/TAX1BP1 signaling in pancreatic ductal adenocarcinoma.
Shang M; Weng L; Xu G; Wu S; Liu B; Yin X; Mao A; Zou X; Wang Z
J Cell Physiol; 2021 Oct; 236(10):6868-6883. PubMed ID: 33629745
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA-155 Controls Exosome Synthesis and Promotes Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma.
Mikamori M; Yamada D; Eguchi H; Hasegawa S; Kishimoto T; Tomimaru Y; Asaoka T; Noda T; Wada H; Kawamoto K; Gotoh K; Takeda Y; Tanemura M; Mori M; Doki Y
Sci Rep; 2017 Feb; 7():42339. PubMed ID: 28198398
[TBL] [Abstract][Full Text] [Related]
10. Melittin inhibits tumor growth and decreases resistance to gemcitabine by downregulating cholesterol pathway gene CLU in pancreatic ductal adenocarcinoma.
Wang X; Xie J; Lu X; Li H; Wen C; Huo Z; Xie J; Shi M; Tang X; Chen H; Peng C; Fang Y; Deng X; Shen B
Cancer Lett; 2017 Jul; 399():1-9. PubMed ID: 28428074
[TBL] [Abstract][Full Text] [Related]
11. Enhancing sorafenib-mediated sensitization to gemcitabine in experimental pancreatic cancer through EMAP II.
Awasthi N; Zhang C; Hinz S; Schwarz MA; Schwarz RE
J Exp Clin Cancer Res; 2013 Mar; 32(1):12. PubMed ID: 23497499
[TBL] [Abstract][Full Text] [Related]
12. S100A14 promotes progression and gemcitabine resistance in pancreatic cancer.
Zhu H; Gao W; Li X; Yu L; Luo D; Liu Y; Yu X
Pancreatology; 2021 Apr; 21(3):589-598. PubMed ID: 33579599
[TBL] [Abstract][Full Text] [Related]
13. TIMP1 down-regulation enhances gemcitabine sensitivity and reverses chemoresistance in pancreatic cancer.
Tan Y; Li X; Tian Z; Chen S; Zou J; Lian G; Chen S; Huang K; Chen Y
Biochem Pharmacol; 2021 Jul; 189():114085. PubMed ID: 32522594
[TBL] [Abstract][Full Text] [Related]
14. Targeted nuclear factor-kappaB suppression enhances gemcitabine response in human pancreatic tumor cell line murine xenografts.
Waters JA; Matos J; Yip-Schneider M; Aguilar-Saavedra JR; Crean CD; Beane JD; Dumas RP; Suvannasankha A; Schmidt CM
Surgery; 2015 Oct; 158(4):881-8; discussion 888-9. PubMed ID: 26209568
[TBL] [Abstract][Full Text] [Related]
15. Inhibiting signal transducer and activator of transcription-3 increases response to gemcitabine and delays progression of pancreatic cancer.
Venkatasubbarao K; Peterson L; Zhao S; Hill P; Cao L; Zhou Q; Nawrocki ST; Freeman JW
Mol Cancer; 2013 Sep; 12(1):104. PubMed ID: 24025152
[TBL] [Abstract][Full Text] [Related]
16. Combined targeting of histone deacetylases and hedgehog signaling enhances cytoxicity in pancreatic cancer.
Chun SG; Zhou W; Yee NS
Cancer Biol Ther; 2009 Jul; 8(14):1328-39. PubMed ID: 19421011
[TBL] [Abstract][Full Text] [Related]
17. Integrated stress response is critical for gemcitabine resistance in pancreatic ductal adenocarcinoma.
Palam LR; Gore J; Craven KE; Wilson JL; Korc M
Cell Death Dis; 2015 Oct; 6(10):e1913. PubMed ID: 26469962
[TBL] [Abstract][Full Text] [Related]
18. Dissociation of gemcitabine sensitivity and protein kinase B signaling in pancreatic ductal adenocarcinoma models.
Pham NA; Tsao MS; Cao P; Hedley DW
Pancreas; 2007 Oct; 35(3):e16-26. PubMed ID: 17895832
[TBL] [Abstract][Full Text] [Related]
19. The long non-coding RNA HOTTIP promotes progression and gemcitabine resistance by regulating HOXA13 in pancreatic cancer.
Li Z; Zhao X; Zhou Y; Liu Y; Zhou Q; Ye H; Wang Y; Zeng J; Song Y; Gao W; Zheng S; Zhuang B; Chen H; Li W; Li H; Li H; Fu Z; Chen R
J Transl Med; 2015 Mar; 13():84. PubMed ID: 25889214
[TBL] [Abstract][Full Text] [Related]
20. Histone deacetylase class-I inhibition promotes epithelial gene expression in pancreatic cancer cells in a BRD4- and MYC-dependent manner.
Mishra VK; Wegwitz F; Kosinsky RL; Sen M; Baumgartner R; Wulff T; Siveke JT; Schildhaus HU; Najafova Z; Kari V; Kohlhof H; Hessmann E; Johnsen SA
Nucleic Acids Res; 2017 Jun; 45(11):6334-6349. PubMed ID: 28369619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
